2025年1月22日 · Inclisiran is used to lower LDL-C (low-density lipoprotein cholesterol) levels alongside diet and statin therapy in adults with high cholesterol caused by genetic reasons (primary hyperlipidemia).

Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). [5][7][6][9] It is a small interfering RNA ...

Inclisiran injection is used together with a proper diet, alone or together with other medicines (eg, statins), to treat heterozygous familial hypercholesterolemia (HeFH) in patients who need additional lowering of their LDL cholesterol.

LEQVIO is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the...

Inclisiran is a cholesterol-lowering treatment that reduces levels of a ‘bad’ cholesterol, called low-density lipoprotein (LDL) cholesterol, in the blood. High LDL cholesterol is a well-known risk …

2024年9月25日 · Leqvio (inclisiran) is commonly used to lower bad cholesterol levels (LDL-C) in people born with a genetic condition affecting how the body removes cholesterol from the blood (including...

2023年11月24日 · Learn about the side effects of inclisiran, from common to rare, for consumers and healthcare professionals.

Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels with only two or three injections per year.

2023年1月5日 · Inclisiran is a first-in-class small interfering ribonucleic acid (siRNA) therapy which prevents hepatic PCSK9 production and can be administered every 6 months (after initial and 3-month doses) providing a convenient approach to lower LDL cholesterol.

Inclisiran (Leqvio) was previously reviewed by CADTH in February 2022 for the same indication, and the recommendation was to not reimburse. 27 Key reasons for this recommendation included the fact that there was insufficient evidence that inclisiran reduces CV morbidity and mortality, or all-cause mortality, as the pivotal trials — ORION-9 ...